Quantitative Systems Pharmacology‐Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe Disease
Clinical Pharmacology & Therapeutics · 2025-02 · 117 (2) · 579-588
DOI: 10.1002/cpt.3498 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 04.12.2024. Verfasst von Chanchala Kaddi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Translational Disease Modeling, Translational Medicine and Early Development, Sanofi, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Glycogen Storage Disease Type II, Enzyme Replacement Therapy, alpha-Glucosidases, Network Pharmacology. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Sanofi.
Abstract (Originalsprache)
Pompe disease is a rare, progressive neuromuscular disease caused by deficient lysosomal glycogen degradation, and includes both late‐onset (LOPD) and severe infantile‐onset (IOPD) phenotypes. Due to very small patient numbers in IOPD and the high phenotypic heterogeneity observed in this population, a quantitative systems pharmacology (QSP)‐based “digital twin” approach was developed to perform an in silico comparison of the efficacy of avalglucosidase alfa vs. the standard of care, in a virtual population of IOPD patients. A QSP model was developed that represents key elements of Pompe disease pathophysiology, including tissue glycogen accumulation and the elevation of the biomarker urine Hex4 in both LOPD and IOPD patients. In this approach, the QSP model was used to generate digital twins of each IOPD patient enrolled in the avalglucosidase alfa clinical program, considering their respective disease burden, demographics, and treatment history. This virtual cohort supplemented clinical observations by simulating and comparing tissue glycogen and urine Hex4 following avalglucosidase alfa treatment vs. the standard of care. The digital twin analysis supports the interpretation that the enhanced reduction in urine Hex4 observed following avalglucosidase alfa treatment is attributable to greater tissue glycogen clearance. Overall, this study provides mechanism‐based insight into avalglucosidase alfa efficacy across the phenotypic spectrum of Pompe disease and demonstrates the value of applying a QSP‐based digital twin analysis to support rare disease drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Translational Disease Modeling, Translational Medicine and Early Development, Sanofi, Cambridge, Massachusetts, USA.
- Translational Disease Modeling, Translational Medicine and Early Development, Sanofi, Bridgewater, New Jersey, USA.
- Certara Applied Biosimulation, Lawrenceville, New Jersey, USA.
- Global Medical Affairs, Sanofi, Cambridge, Massachusetts, USA.
- Certara Applied Biosimulation, Princeton, New Jersey, USA.
- Certara Applied Biosimulation, Canterbury, UK.
Förderung
- Sanofi
Zitieren
APA
Kaddi, C., Tao, M., Bergeler, S., George, K., Geerts, H., van der Graaf, P. H., Batista, J. L., Foster, M., Ortemann-Renon, C., Zaher, A., An Haack, K., & Zaph, S. (2025). Quantitative Systems Pharmacology‐Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe Disease. Clinical Pharmacology & Therapeutics, 117(2), 579-588. https://doi.org/10.1002/cpt.3498
Vancouver
Kaddi C, Tao M, Bergeler S, George K, Geerts H, van der Graaf PH, et al. Quantitative Systems Pharmacology‐Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe Disease. Clinical Pharmacology & Therapeutics. 2025;117(2):579-588. doi:10.1002/cpt.3498
BibTeX
@article{Kaddi2025,
author = {Kaddi, Chanchala and Tao, Mengdi and Bergeler, Silke and George, Kelly and Geerts, Hugo and van der Graaf, Piet H and Batista, Julie L and Foster, Meredith and Ortemann-Renon, Catherine and Zaher, Atef and An Haack, Kristina and Zaph, Susana},
title = {Quantitative Systems Pharmacology‐Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe Disease},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
volume = {117},
number = {2},
pages = {579--588},
doi = {10.1002/cpt.3498}
}
EUVIMED